Evidence map›Paper›PMID 42713220›Full record

ArticleVaccine: X2026

Parameters Affecting Dengue Virus Replication in Vero Cells.

Md Muzammal Haque Asim, Arman Mahmud Khan, Tasmina Ferdous Susmi, F M Ashik Mahmud, Ahmed Zubayer, Md Tunvir Mozid, Rudhra Rayhan, Md Muktadir Rahman Ashik, Shamima Nasrin, Imran Khan and 5 more

Abstract read
In one paragraph

Article in Vaccine: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Md Muzammal Haque AsimResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Arman Mahmud KhanResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Tasmina Ferdous SusmiResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
F M Ashik MahmudResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Ahmed ZubayerResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Md Tunvir MozidResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Rudhra RayhanResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Md Muktadir Rahman AshikResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Shamima NasrinResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Imran KhanResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Mahbubul KarimResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Hasneen MuktadirResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Abdul MuktadirResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.
Stephen S WhiteheadLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 3W10A, Building 33, 33 North Drive, Bethesda, MD 20892, USA.
Mohammad Mainul AhasanResearch & Development, Vaccine Division, Incepta Pharmaceuticals Ltd., Dhaka 1341, Bangladesh.

Funding

Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

Dengue has become a global threat affecting millions of people annually and contributing to a significant mortality burden. Vaccination is the most effective approach to prevent this disease in dengue-endemic regions. A thorough understanding of viral growth kinetics is critical for designing a robust and scalable vaccine manufacturing process. The current study aimed to optimize the key growth parameters of four recombinant live attenuated dengue serotypes, including harvest schedule, temperature, Multiplicity of infection (MOI), and metabolite concentration. Growth kinetics data, followed by a scale-up study, established the feasibility of multiple harvests for all four serotypes within a defined production window, with the first harvest optimally occurring between Days 4 and 8. All serotypes demonstrated strong responsiveness to low MOIs and temperature shifts, resulting in 2- to 25-fold increases in titer within a reduced time frame. Furthermore, metabolite profiling revealed distinct glutamine and glucose consumption dynamics, highlighting its importance for optimizing infection media. Taken together, these findings provide valuable insights into dengue virus production and define critical parameters that can support future optimization studies and large-scale production.

Indexed as

growth parametersoptimizationrecombinant live attenuated dengue serotypes

Identifiers

PMID42713220
PMCPMC13552442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.